title: [Influences of the genotypes of HBV and HBeAg regarding their response to PEG-IFN in chronic hepatitis B patients].
abstract: OBJECTIVE
  To study the effects of genotypes of HBV and HBeAg on the response to PEG-interferon alpha (PEG-IFN) in chronic hepatitis B (CHB) patients.
  
  
  METHODS
  PCR-RFLP and S gene sequencing were conducted in 42 CHB patients.
  
  
  RESULTS
  The sustained response (SR) rates were 66.7% in genotype B and 27.3% in genotype C group. The P value was 0.039 by the Pearson Chi-square test, while it was 0.06 by the Fisher's exact test. The results suggested a trend that patients with genotype B HBV compared to genotype C had better SR to PEG-IFN therapy, although the difference was not significant. Results also showed that SR rate in patients with HBeAg-negative CHB (7/8 87.5%) was significantly higher than that in HBe+ CHB patients (8/21 38.1%, P < 0.05).
  
  
  CONCLUSIONS
  Our results indicate that HBV genotype and HBeAg, especially the later, are main factors for predicting PEG-IFN therapy response in CHB patients.
authors.affiliation: Department of Infectious Diseases, Nanfang Hospital, Nanfang Medical University, Guangzhou 510515, China.
authors.forename: He-bin
authors.initials: HB
authors.lastname: Fan
authors.forename: Ya-bing
authors.initials: YB
authors.lastname: Guo
authors.forename: Kang-xian
authors.initials: KX
authors.lastname: Luo
authors.forename: Jin-lin
authors.initials: JL
authors.lastname: Hou
authors.forename: Zhan-hui
authors.initials: ZH
authors.lastname: Wang
authors.forename: Ming-xia
authors.initials: MX
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D006513:Hepatitis B e Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000235:genetics* / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a